Meglitinides for type 2 diabetes

References

Citations

  1. Rosenstock J, et al. (2004). Repaglinide versus nateglinide monotherapy. Diabetes Care, 27(6): 1265–1270.

  2. Lebowitz HE (2005). Management of hyperglycemia with oral antihyperglycemic agents in type 2 diabetes. In CR Kahn et al., eds., Joslin's Diabetes Mellitus, 14th ed., pp. 687–710. Philadelphia: Lippincott Williams and Wilkins.


Author: Merrill Hayden
Carrie Henley		Last Updated: November 27, 2006
Medical Review: Adam Husney, MD - Family Medicine
Caroline S. Rhoads, MD - Internal Medicine
Hanan Bassyouni, MD - Endocrinology and Metabolism
Matthew I. Kim, MD - Endocrinology & Metabolism

© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.

Click here to learn about Healthwise
Click here to learn about Healthwise
Topic Contents
 Examples
 How It Works
 Why It Is Used
 How Well It Works
 Side Effects
 What To Think About
 References